Medication info
Polmin Empagliflozin and Metformin Extended Release Tablets 25/1000 mg

Polmin Empagliflozin and Metformin Extended Release Tablets 25/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Green Cross Corporation
Appearance
Light yellow, double convex, oval-shaped extended-release film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501715 · Approved 2025.07.09 · Insurance code 643606900

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse Reactions and 6. Interactions). Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows: - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately. For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Green Cross Corporation

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Blood sugar control in adult patients with type 2 diabetes
View approved original text

This medication is used to improve blood sugar control in adults with type 2 diabetes through the combined administration of empagliflozin and metformin, in conjunction with dietary and exercise therapy. In particular, it is crucial to follow the instructions of healthcare professionals for adult patients with type 2 diabetes who have inadequate blood sugar control and cardiovascular disease, as there is a heightened risk of cardiovascular events. This medication aids in diabetes management and stabilizing blood sugar levels.

How to take

Adult dose

The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse Reactions and 6. Interactions). Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows: - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately. For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used in the treatment of diabetes and helps in controlling blood sugar levels. Caution is needed as there is a risk of a rare side effect known as severe lactic acidosis while taking this medication. Lactic acidosis can result in dangerous conditions due to excessive accumulation of lactic acid in the body, posing a risk to life. Furthermore, one should be wary of hypoglycemia when taking this medication in conjunction with other drugs that lower blood sugar, such as insulin or sulfonylureas. This medication should not be administered to patients with impaired kidney function or certain heart diseases, acute infections, or severe liver dysfunction. Before undergoing tests or surgery, this medication should be temporarily discontinued and can be resumed once kidney function returns to normal. During the use of this medication, if symptoms of dehydration, diarrhea, or vomiting occur, one must consult a physician immediately, especially for elderly patients or those at risk of reduced fluid volume. This medication can cause genital infections or urinary tract infections, and prompt treatment should be sought if related symptoms appear. Moreover, levels of vitamin B12 may decrease, so regular blood tests are recommended for long-term use. It is safest for women who are pregnant or may become pregnant to avoid this medication, as well as nursing mothers to refrain from taking it. This medication has not been confirmed for safety and efficacy in children, thus is not recommended for patients under 18. In cases of overdose, severe side effects such as hypoglycemia or lactic acidosis may occur, so adherence to the prescribed dosage is vital; if any unusual symptoms arise, seek immediate medical care. It is advisable to avoid alcohol consumption during the course of this medication, and potential drug interactions must be discussed with a physician or pharmacist before concurrent use with other medications. Lastly, this medication should be swallowed whole, without breaking, crushing, or chewing the tablets; it is normal for the tablet coating to appear in the stool.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
Show 191 more
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • hypoglycemic episodes
  • decreased fluid volume
  • weight loss
  • urinary tract infection
  • urosepsis
  • pyelonephritis
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic adenocarcinoma
  • constipation
  • gastritis
  • gastrointestinal disorders
  • oral discomfort
  • salivary gland pain
  • headache
  • dizziness
  • asthenia
  • chest discomfort
  • chest pain
  • fever
  • chills
  • strange sensation
  • edema
  • pain
  • vascular stent stenosis
  • vascular stent thrombosis
  • urinary calculi
  • hematuria
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervicitis
  • vaginal discharge
  • hyperglycemia
  • dyslipidemia
  • hyponatremia
  • dermal cysts
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal deposits
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • nasal bleeding
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • traffic accident
  • splenic injury
  • sternal fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular disease
  • peripheral artery obstructive disease
  • benign tumors of the ampulla of Vater
  • benign ovarian tumors
  • bladder cancer
  • cholesteatoma
  • stomach cancer
  • leiomyoma
  • pancreatic adenocarcinoma
  • rectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • anxiety
  • depression
  • sleep disorders
  • dysmenorrhea
  • positional vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodules
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colon bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • acute pyelonephritis
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • elevated alanine aminotransferase
  • elevated aspartate aminotransferase
  • ureterolithiasis
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • cervicitis
  • hyperglycemia
  • hyponatremia
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture; therefore, it should be stored in a tightly sealed container. Additionally, it is advised to keep it at room temperature, neither too hot nor too cold, ideally between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Light yellow, double convex, oval-shaped extended-release film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.